Document is current
Any future updates will be listed below
-
Authors
Häkkinen, Katja https://orcid.org/0000-0001-8222-7505
Kiiski, Johanna I.
Lähteenvuo, Markku https://orcid.org/0000-0002-7244-145X
Jukuri, Tuomas
Suokas, Kimmo https://orcid.org/0000-0001-6296-6343
Niemi-Pynttäri, Jussi
Kieseppä, Tuula
Männynsalo, Teemu
Wegelius, Asko
Haaki, Willehard
Lahdensuo, Kaisla
Kajanne, Risto https://orcid.org/0000-0002-3405-7115
Kaunisto, Mari A. https://orcid.org/0000-0002-6946-9195
Tuulio-Henriksson, Annamari
Kampman, Olli https://orcid.org/0000-0001-6891-2266
Hietala, Jarmo
Veijola, Juha
Lönnqvist, Jouko
Isometsä, Erkki
Paunio, Tiina
Suvisaari, Jaana https://orcid.org/0000-0001-7167-0990
Kalso, Eija https://orcid.org/0000-0002-4899-605X
Niemi, Mikko https://orcid.org/0000-0003-4550-2189
Tiihonen, Jari https://orcid.org/0000-0002-0400-6798
Daly, Mark
Palotie, Aarno
Ahola-Olli, Ari V.
- License Information
-
More Information
Article History
Received: 12 July 2021
Revised: 1 February 2022
Accepted: 8 February 2022
First Online: 23 February 2022
Competing interests
: ML is a board member of Genomi Solutions ltd. and Nursie Health ltd., has received honoraria from Sunovion ltd., Orion Pharma ltd., Otsuka ltd. and Janssen-Cilag. Part of MK’s and RK’s salaries are covered by a large Finnish biobank study FinnGen, funded by twelve international pharmaceutical companies (Abbvie, AstraZeneca, Biogen, Celgene, Genentech, GSK, Janssen, Maze Therapeutics, Merck/MSD, Novartis, Pfizer and Sanofi) and Business Finland. JT has participated in research projects funded by grants from Janssen-Cilag and Eli Lilly to his employing institution, has received honoraria from Eli Lilly, Janssen-Cilag, Lundbeck and Otsuka, and is a member of advisory board for Lundbeck. AVA is an employee and shareholder of Abomics, a company providing pharmacogenetic consultation services. The other authors declare no conflict of interest.
